AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

- 1.-166. (Canceled).
- 167. (Currently Amended) A method of therapeutic or prophylactic treatment comprising the steps of:
- (a) implanting a silicon implant into a human or animal, the implant comprising a drug and hydrophobic resorbable mesoporous silicon having a pore size between 20 A and 500 A, the drug being at least partly located in the pores of the porous silicon; and
 - (b) allowing the porous silicon to erode.
- 168. (Currently Amended) A methodsilicon implant according to claim 167 wherein the porous silicon comprises macroporous silicon.
 - 169. (Canceled).
- 170. (Currently Amended) A methodsilicon implant according to claim 167 wherein the resorbable mesoporous silicon has a porosity between 2% and 80%.
- 171. (Currently Amended) A methodsilicon implant according to claim 170 wherein the resorbable mesoporous silicon has a porosity between 4% and 55%.
- 172. (Currently Amended) A methodsilicon implant according to claim 167 wherein the resorbable mesoporous silicon has a structure such that it is tissue compatible.
- 173. (Currently Amended) A methodsilicon implant according to claim 167 wherein in step (b) the resorbable mesoporous silicon erodes over an interval of between one month and two years.

CANHAM et al. Appl. No. 09/647,599 January 10, 2006

- 174. (Currently Amended) A method silicon implant according to claim 167 wherein the implant has a largest dimension x, wherein $0 < x \le 2$ mm.
- 175. (Currently Amended) A methodsilicon implant according to claim 167 wherein the drug is distributed through substantially the whole volume of the material of said implant.
- 176. (Currently Amended) A methodsilicon implant according to claim 167 wherein the implant comprises substantially entirely resorbable mesoporous silicon.